[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].

Bo Wang, Bin Wang, Lianbin Zhang, Xiangyang Chu, Gang YuPubMed 2013 · DOI

TL;DR

This study investigates the relationship between the expression of two key drug resistance genes, TUBB3 and STMN1, and mutations in the EGFR signaling pathway in non-small cell lung cancer (NSCLC). The findings suggest that mutations in EGFR and KRAS may play a significant role in regulating TUBB3/STMN1 expression, offering potential new avenues for predicting and overcoming chemotherapy resistance in NSCLC patients.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. While chemotherapy has been a cornerstone of treatment, a significant challenge is the development of drug resistance, leading to poor patient outcomes. Specifically, resistance to antimicrotubule agents, commonly used in NSCLC treatment, is a major concern. TUBB3 and STMN1 are known to be involved in this resistance. However, the precise mechanisms by which these resistance factors are regulated, particularly in relation to other critical molecular pathways in cancer, remain incompletely understood. This paper aims to bridge this gap by exploring the correlation between the expression levels of TUBB3 and STMN1 and the mutational status of key genes within the epidermal growth factor receptor (EGFR) signaling pathway, which is frequently dysregulated in NSCLC. Understanding these relationships could provide valuable insights for personalized treatment strategies and overcoming therapeutic resistance.

Methods

The researchers employed a retrospective study design, analyzing tumor specimens from 46 NSCLC patients. To quantify the expression levels of TUBB3 and STMN1 mRNA, they utilized a branched DNA-liquid chip assay. This method allows for direct detection of mRNA without the need for RNA extraction, purification, or reverse transcription, potentially offering greater accuracy and robustness. For detecting mutations in the EGFR, KRAS, BRAF, and PI3K genes, the study utilized the xTAG liquid chip technology. This multiplex assay enables the simultaneous detection of various mutations within these key signaling pathway genes. Statistical analysis was performed using SPSS software, with Spearman correlation analysis employed to assess the relationships between gene expression and gene mutations, as the data did not conform to a normal distribution.

Datasets

The study utilized tumor specimens from 46 NSCLC patients diagnosed and treated at the General Hospital of the People's Liberation Army. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Co-expression of Resistance Markers: TUBB3 and STMN1, both implicated in antimicrotubule drug resistance, exhibit strong co-expression. This suggests they may function in concert or be regulated by common pathways in conferring resistance.
  • EGFR Mutations Influence Resistance Gene Expression: The study found a negative correlation between EGFR E21 mutations and TUBB3 expression, indicating that the presence of this specific EGFR mutation is associated with lower TUBB3 levels. Conversely, wild-type EGFR E21 was linked to higher TUBB3 expression.
  • KRAS Mutations Drive Resistance Gene Expression: A positive correlation was observed between KRAS E2 mutations and STMN1 expression, suggesting that KRAS E2 mutations may lead to increased STMN1 levels, potentially enhancing drug resistance.
  • EGFR and KRAS as Regulators: The findings collectively point towards EGFR and KRAS mutations as significant factors that can influence the expression of TUBB3 and STMN1. This highlights the interconnectedness of signaling pathways in cancer progression and drug resistance.

Key Results

  • TUBB3 and STMN1 Co-expression: High expression of TUBB3 was significantly associated with high expression of STMN1 (P=0.006).
  • EGFR E21 Mutation and TUBB3: EGFR E21 mutations were negatively correlated with TUBB3 expression (P=0.004). Wild-type EGFR E21 was associated with higher TUBB3 expression.
  • KRAS E2 Mutation and STMN1: KRAS E2 mutations were positively associated with STMN1 expression (P=0.038).
  • EGFR Mutation Rate: The study reported an EGFR mutation rate of 50% (23/46) and a KRAS mutation rate of 13.1% (6/46) in their cohort.

Limitations and Future Work

The authors acknowledge that the sample size of 46 patients is relatively small, which may limit the statistical power to detect significant differences in correlations between genes and clinical-pathological features. They also note that follow-up data for survival analysis is still being collected. Future work should focus on expanding the sample size to validate these findings and to further investigate the precise molecular mechanisms by which EGFR and KRAS mutations regulate TUBB3/STMN1 expression. The study also suggests that combining multiple molecular markers for personalized treatment strategies could provide more comprehensive insights. Further research is needed to explore the role of BRAF and PI3K mutations in regulating TUBB3/STMN1 expression, as these were not statistically significant in this study due to low mutation frequencies.

Summary updated

Abstract

Antimicrotubule drug resistance factors of TUBB3 and STMN1 may be related with mutations of EGFR signal pathway, suggesting that EGFR mutation and KRAS mutation may be important factors in regulation of TUBB3/STMN1 expression, which provided basic references for chemotherapeutic resistance.
BibTeX
@inproceedings{wang2013correlation,
  author = {Bo Wang and Bin Wang and Lianbin Zhang and Xiangyang Chu and Gang Yu},
  title = {{[Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].}},
  booktitle = {PubMed},
  year = {2013},
  doi = {10.3779/j.issn.1009-3419.2013.10.09},
}
Figure